1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Baseline Productions, Inc.

Baseline Productions, Inc.

BSSP
Baseline Productions, Inc.US flagOther OTC
0.00
USD
- -
- -
74,377.00Market Cap
Baseline Productions, Inc.
BSSP
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
TTM
FRC
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
-0.01
-0.01
-0.02
Basic EPS, GAAP
- -
- -
- -
- -
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
-0.01
-0.02
-0.04
Book Value per Share
- -
- -
- -
-0.01
-0.02
Tangible Book Value per Share
62
75
37
37
41
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
-353.57
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
-1
Net Income, GAAP
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-402.8
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
-1
Working Capital
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
-1
Total Equity
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'15
Jun'15
Sep'15
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
37
37
57
Market Capitalization
4
5
- -

Working Capital

FRC

•

in mil. unless spec.
Mar'15
Jun'15
Sep'15
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
1
1
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
230.03%
Free Cash Flow
- -
- -
133.9%
Net Income, GAAP
- -
- -
134.2%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
-0.01
2014
- -
- -
- -
- -
-0.01
2015
- -
-0.01
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -
Similar Companies
Tryp Therapeutics Inc. (TRYP.CN)
Anebulo Pharmaceuticals, Inc. (ANEB)
Neurobiological Technologies, Inc. (NTII)
Dyadic International, Inc. (DYAI)
Paradigm Biopharmaceuticals Limited (PBIGF)
Longeveron Inc. (LGVN)
Business
Baseline Productions, Inc. (BSSP) operates without significant ongoing business activities in the biotechnology sector. The company previously develops immunotherapeutic-based technologies focused on cancer treatments and infectious diseases, including the patented Irreversible Pepsin Fraction (IPF) platform for broad therapeutic applications free from common side effects; it suspends operations related to capital purchase divisions and related mobile hardware and software products. Baseline Productions maintains a minimal operational footprint headquartered in Scottsdale, Arizona, with activities spanning the United States since its founding in 2010. Recent strategic shifts include the rescission of a 2016 purchase agreement with Cantech Pharma, Inc. in 2017 due to inability to proceed with licensing for Mexico; suspension of management activities for proof-of-concept development owing to funding shortfalls; and ongoing efforts since 2021 to complete merger and acquisition negotiations while pursuing regulatory compliance. The company relocates its principal address to 5423 E. Piping Rock Road, Scottsdale, Arizona 85254 in February 2021, reflecting operational adjustments amid dormant status. No active subsidiaries, parent relationships, or recent funding rounds, partnerships, or product launches occur within the last two years, positioning Baseline Productions as a development-stage entity targeting potential reactivation through external transactions.